<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02473952</url>
  </required_header>
  <id_info>
    <org_study_id>GTI1408</org_study_id>
    <nct_id>NCT02473952</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate whether IGIV-C improves MG symptoms as compared to
      placebo in subjects with MG.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate the efficacy of IGIV-C in subjects with generalized
      myasthenia gravis (MG) on standard of care treatment at study entry in terms of improvement
      in MG symptoms as measured by the mean change in Quantitative Myasthenia Gravis (QMG) score
      from Baseline (Week 0) to Week 24 as compared to placebo.

      The safety objective of this study is to evaluate the safety and tolerability of IGIV-C
      loading dose of 2 g/kg followed by 7 maintenance dosages of 1 g/kg every 3 weeks through Week
      21 in subjects with MG.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in myasthenia gravis (MG) symptoms as measured by the mean change in QMG score.</measure>
    <time_frame>from Baseline (Week 0) to Week 24</time_frame>
    <description>To measure improvement in MG symptoms by the mean change in Quantitative myasthenia gravis (QMG) score from Baseline (Week 0) to Week 24 as compared to placebo.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Myasthenia Gravis, Generalized</condition>
  <arm_group>
    <arm_group_label>IGIV-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified.
An initial loading dose of 2 g/kg of body weight will be administered at Baseline (Week 0, Visit 1) followed by maintenance doses of 1 g/kg of body weight administered every third week through Week 21 (Visit 8).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: Sterile 0.9% sodium chloride injection or equivalent. Placebo will be infused at the Baseline/Week 0 Visit (Visit 1) using the same volume as would be required for the IGIV-C loading dose. Subsequent placebo maintenance doses will be matched in volume to the IGIV-C maintenance doses and administered every third week until Week 21 (Visit 8).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IGIV-C</intervention_name>
    <description>IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified</description>
    <arm_group_label>IGIV-C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Anti-acetylcholine receptor (AChR) antibody positive

          -  Confirmed diagnosis of generalized myasthenia gravis (MG).

          -  Myasthenia Gravis Foundation of America (MGFA) classification of Class II, III, or IVa
             inclusive at Screening.

          -  QMG &gt;= 10 at Screening. Note: Subjects who only have a history of ocular MG may not
             enroll.

          -  Receiving standard of care MG treatment at a stable dose consisting of any one of the
             following for the time intervals delineated below (time intervals apply to medications
             and maintenance of stable dose level):

               1. Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks
                  prior to Screening and no immunosuppressants

               2. Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks
                  prior to Screening AND/OR only one of the following:

                    1. Prednisone (up to 60 mg/day or equivalent) for at least 2 months prior to
                       Screening, OR

                    2. Azathioprine for at least 6 months prior to Screening, OR

                    3. Mycophenolate mofetil for at least 6 months prior to Screening, OR

                    4. Methotrexate for at least 6 months prior to Screening, OR

                    5. Cyclosporine or tacrolimus for at least 3 months prior to Screening

               3. Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks
                  prior to Screening AND/OR prednisone (up to 60 mg/day or equivalent) for at least
                  one month prior to Screening and only one of the following:

                    1. Azathioprine for at least 6 months prior to Screening, OR

                    2. Mycophenolate mofetil for at least 6 months prior to Screening, OR

                    3. Methotrexate for at least 6 months prior to Screening, OR

                    4. Cyclosporine or tacrolimus for at least 3 months prior to Screening

        Exclusion Criteria:

          -  Have received cyclophosphamide or any other immunosuppressive agent apart from the
             ones allowed per inclusion criteria within the past 6 months

          -  Any change in MG treatment regimen between Screening (Week -3, Visit 0) and Baseline
             (Week 0, Visit 1)

          -  Greater than two point change in QMG score, increased or decreased, between Screening
             (Week -3, Visit 0) and Baseline (Week 0, Visit 1)

          -  Any episode of myasthenic crisis in the one month prior to Screening

          -  Evidence of malignancy within the past 5 years (non-melanoma skin cancer, carcinoma in
             situ of cervix is allowed) or thymoma potentially requiring surgical intervention
             during the course of the trial (intent to perform thymectomy)

          -  Thymectomy within the preceding 6 months

          -  Rituximab, belimumab, eculizumab or any monoclonal antibody used for immunomodulation
             within the past 12 months

          -  Have received immune globulin (Ig) treatment given by intravenous (IV), subcutaneous,
             or intramuscular route within the last 3 months

          -  Current known hyperviscosity or hypercoagulable state

          -  Currently receiving anti-coagulation therapy (vitamin K antagonists, nonvitamin K
             antagonist oral anticoagulants [e.g., dabigatran etexilate, rivaroxaban, edoxaban, and
             apixaban], parenteral anticoagulants [e.g., fondaparinux]). Note that oral
             anti-platelet agents are allowed (e.g., aspirin, clopidogrel, ticlodipine)

          -  Documented diagnosis of thrombotic complications to polyclonal intravenous
             immunoglobulin (IVIg) therapy in the past

          -  History of recent (within the last year) myocardial infarction or stroke

          -  Uncontrolled congestive heart failure; embolism; or historically documented (within
             the last year) electrocardiogram (ECG) changes indicative of myocardial ischemia or
             atrial fibrillation

          -  History of chronic alcoholism or illicit drug abuse (addiction) in the 12 months
             preceding the Screening/Week -3 (Visit 0)

          -  Plasma exchange (PLEX) performed within the last 3 months

          -  Renal impairment (i.e., serum creatinine exceeds more than 1.5 times the upper limit
             of normal [ULN] for the expected normal range for the testing laboratory).

          -  Hemoglobin levels less than 9 g per dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Phoenix Neurological Associates, Ltd.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California-Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida at Shands Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute, Inc.</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers New Jersey Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network (UHN) - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno, Dept of Neurologicka klinika</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice - Hôpital de l'Archet 1, Ctre de Réf Maladies Neuromusculaires et SLA</name>
      <address>
        <city>Nice cedex 3</city>
        <state>Alpes Maritimes</state>
        <zip>6202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg - Nouvel Hôpital Civil, Clinique Neurologique</name>
      <address>
        <city>Strasbourg cedex</city>
        <state>Bas Rhin</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital Purpan, Service de Neurologie Générale</name>
      <address>
        <city>Toulouse cedex 9</city>
        <state>Haute Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Neurologique Pierre Wertheimer, Neuro-musculaire - Electromyographie</name>
      <address>
        <city>Bron cedex</city>
        <state>Rhone</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Regensburg, Parent</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin Göttingen, Parent</name>
      <address>
        <city>Göttingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln, Neurologie und Psychiatrie</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria Halle-Doelau, Klinik fuer Neurologie</name>
      <address>
        <city>Halle</city>
        <state>Sachsen Anhalt</state>
        <zip>6120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus TU Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Jena, Klinik fuer Neurologie</name>
      <address>
        <city>Jena</city>
        <state>Thueringen</state>
        <zip>7747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik fuer Neurologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc Del-pesti Korhaz es Rendelointezet, Neurologiai Osztaly</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pest Megyei Flor Ferenc Korhaz, Neurologia es Stroke Osztaly</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kaunas Clinics</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne, Dept of Neurology</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii Klinicznej</name>
      <address>
        <city>Krakow</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III Szpital Miejski w Lodzi im. Dr K. Jonschera</name>
      <address>
        <city>Lodz</city>
        <zip>93-113</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny, Dept of Neurology</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2015</study_first_submitted>
  <study_first_submitted_qc>June 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2015</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Myasthenia Gravis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

